Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffer Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Recovery and Survival of EryDex in Non-patient Volunteers

NCT02380924
View directory record Official record
Conditions
Healthy
Interventions
DSP loaded RBC using EryDex System, Sham treated RBC using the EryDex System
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

NCT00223899
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
VCL-IM01 (encoding IL-2) with Electroporation
Genetic
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

NCT06394830
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
VNX001
Drug
Lead sponsor
Vaneltix Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Fresno, California • Tustin, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

NCT01227564
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

NCT03126318
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
COR-001, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 23, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

NCT01999192
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tregalizumab, Placebo
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Jet Injection Lidocaine for Blood Draws in Young Children

NCT01890642
View directory record Official record
Conditions
Pain
Interventions
J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose
Device · Other · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Months to 6 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

NCT02223117
View directory record Official record
Conditions
Healthy
Interventions
Thrombosomes, Placebo
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT04009291
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Montgomery, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

NCT01915212
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HSV529, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

NCT01765426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Galveston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475
View directory record Official record
Conditions
Recurrent Malignant Glioma, Brain Glioblastoma
Interventions
OKN-007, Temozolomide (TMZ)
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT00107107
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Deciphering Preserved Autonomic Function After Spinal Cord Injury

NCT04493372
View directory record Official record
Conditions
Spinal Cord Injuries, Autonomic Imbalance, Autonomic Dysreflexia, Orthostatic Hypotension
Interventions
Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Women With Metastatic Breast Cancer

NCT00849459
View directory record Official record
Conditions
Breast Cancer
Interventions
adenovirus-mediated human interleukin-12
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

NCT06879067
View directory record Official record
Conditions
Safety, Tolerability
Interventions
Placebo, Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety Study of Cosmetic Tissue Augmentation in People of Color

NCT01147172
View directory record Official record
Conditions
Wrinkles
Interventions
Elevess
Device
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Epi-On Corneal Crosslinking for Keratoconus

NCT03245853
View directory record Official record
Conditions
Keratoconus, Keratoconus, Unstable
Interventions
Riboflavin 5'-Phosphate
Drug
Lead sponsor
Comprehensive EyeCare of Central Ohio
Other
Eligibility
14 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 23, 2026, 2:15 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

NCT03907072
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
WVE-210201 (suvodirsen), Placebo
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
5 Years to 12 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 23, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 23, 2026, 2:15 PM EDT